Analyst Andrew Fein of H.C. Wainwright maintained a Buy rating on Palvella Therapeutics, retaining the price target of $270.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Andrew Fein has given his Buy rating due to a combination of factors that highlight both near‑term catalysts and longer‑term platform value. He views the recent SELVA trial success as de‑risking QTORIN rapamycin’s path to approval in microcystic lymphatic malformations (mLM) and setting up a first commercial entry point, with regulatory milestones mapped out through an expected filing in 2026 and potential approval in 2027.
Fein also emphasizes that Palvella is positioning QTORIN as a scalable platform rather than a one‑off asset, with follow‑on opportunities in cutaneous venous malformations, angiokeratomas, and an additional forthcoming indication that collectively expand the addressable market. In his assessment, management’s strategy to pursue streamlined supplemental filings, potential platform technology designation, and broader use in underappreciated settings such as DSAP supports a favorable risk‑reward profile that justifies a Buy recommendation.
In another report released yesterday, BTIG also reiterated a Buy rating on the stock with a $215.00 price target.